Global and United States Waterproofing Chemical Market 2020 Recovering From Covid-19 Outbreak | Know About Leading Manufacturers by Drizoro S.A.U.,…

Global and United States Waterproofing Chemical Market Research Report 2020-2026 provides a comprehensive assessment of the Waterproofing Chemical Market for the forecast from 2020 to 2026, as well as market values for the years 2018 and 2019. The investigatory report provides a close analysis of the impact of COVID-19 on numerous segments within the Waterproofing Chemical market supported product kind, application, and end-use across various countries round the world. Further, the report additionally provides insights into market developments, trends, provide and demand changes across numerous regions across the world. Thereby, the report provides a holistic read on the Waterproofing Chemical Market so as to assist call manufacturers with numerous strategic insights and future outlook. The Waterproofing Chemical market is predicted to witness continuing growth throughout the forecast from 2020 to 2026.

Access Free Sample Copy of Waterproofing Chemical Market Report 2020: https://calibreresearch.com/report/global-waterproofing-chemical-market-34857#request-sample

The report covers numerous aspects of the Waterproofing Chemical market divided into product kind, application and end-use. The report provides market numbers for the years 2018 and 2019 supported actual market findings additionally market estimates for forecast from 2020 to 2026 for every of the merchandise sorts, applications and end-use segments.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

This Waterproofing Chemical Market report has been ready by practised and knowledgeable market analysts and researchers. Its an outstanding compilation of necessary studies that explore the competitive landscape, segmentation, geographical growth, and revenue, production, and consumption growth of the worldwide Waterproofing Chemical market. International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Waterproofing Chemical market.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert https://calibreresearch.com/report/global-waterproofing-chemical-market-34857#inquiry-for-buying

Major Market Players indulged in this report are:

Basf SECarlisle CompaniesConpro Chemicals Private LimitedDrizoro S.A.U.Fosroc International LimitedJohns Manville CorporationMapei S.P.APidilite Industries LimitedSika AgSoprema GroupDowDuPontWacker Chemie AG

Waterproofing Chemical Market 2020 segments by product types:

BitumenElastomersPolyvinyl ChlorideTPOEPDM

The Application of the World Waterproofing Chemical Market 2020-2026 as follows:

Roofing & WallsFloors & BasementsWaste & Water ManagementTunnel LinersOthers

Global and United States Waterproofing Chemical Market Segmentation, By Geography:

North America U.S. Canada Europe UK Germany France Rest of Europe Asia Pacific China Japan India Rest of Asia Pacific Rest of the World Latin America Middle East and Africa

Checkout FREE Report Sample of Waterproofing Chemical Market Report 2020-2026 for Better Understanding: https://calibreresearch.com/report/global-waterproofing-chemical-market-34857#request-sample

The Waterproofing Chemical Market report includes CAGR, market shares, sales, ratio, value, volume, and different very important market figures that offer an explicit image of the expansion of the worldwide Waterproofing Chemical market.

We area unit incessantly watching the market developments and changes occurring as an on the spot or indirect impact of the continued COVID-19 pandemic. Thereby, we have a tendency to area unit during a position to supply info on the market values and trends for each pre-COVID-19 and post-COVID-19 situations.

View original post here:
Global and United States Waterproofing Chemical Market 2020 Recovering From Covid-19 Outbreak | Know About Leading Manufacturers by Drizoro S.A.U.,...

Kanazawa University research: The Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University is organizing the 4th NanoLSI Symposium on 26 and…

KANAZAWA, Japan, Nov. 17, 2020 /PRNewswire/ --The 4th NanoLSI Symposium will be a virtual meeting covering bio-imaging, sensing, and manipulation for medical science. The Nano Life Science Institute (WPI-NanoLSI) was established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology.

Symposium website

https://nanolsi.kanazawa-u.ac.jp/en/4th-sympo/

Flyer

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2020/11/NanoLSI_symposium_2020.jpg

Program details

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2020/11/program.pdf

Nano Life Science Institute (WPI-NanoLSI) aims to acquire a fundamental understanding of various life phenomena, such as development, disease, and aging at the nano-level through transdisciplinary research of Nanometrology, Life Science, Supramolecular Chemistry, and Computational Science.

To further develop interdisciplinary research, the WPI-NanoLSI has organized annual international symposia to build new collaborative relationships with researchers across the world.

This year's fourth symposium will be held online because of restrictions to travel due to the COVID-19 pandemic. To facilitate research exchange that is only possible through online, the WPI-NanoLSI has invited prominent researchers from Europe, North America, and Asia to give talks during the symposium, where each session is scheduled according to the local times of the speakers.

This is an excellent opportunity to gain valuable insights into the latest research findings in bio-imaging, sensing, and manipulation for medical science.

Details

Date: 26 -27 November 2020

Format: Virtual conference (via Zoom) that is free of charge

Timetable

Thursday 26 November

07:40 07:50 (JST) Opening remarks

08:00 10:00 (JST) 1st session

Molecular and cellular dynamics in biological regulation and regenerative medicine

Chair: Prof. Kunio MATSUMOTO/ NanoLSI/CRI

Speakers: Prof. Simon SCHEURING/ Weill Cornell Medicine

Assoc. Prof. Yusuke MIYANARI/ NanoLSI/CRI

Prof. Kenneth S. Zaret/ University of Pennsylvania

Prof. Takanori TAKEBE/ Tokyo Medical and Dental University

10:00 11:00 (JST). Virtual poster session

*Need Separate registration. Please see website

13:30 15:30 (JST) 2nd session

Chemistry-Driven Challenges: from Molecule to Nano/Microscale

Chair: Assoc.Prof. Satoshi ARAI/ NanoLSI

Speakers: Prof. Tomoki OGOSHI/ Kyoto University

Assoc. Prof. Toshinori FUJIE/ Tokyo Institute of Technology

Assoc. Prof. Etsuo SUSAKI/ The University of Tokyo

Prof. Susumu KITAGAWA/ Kyoto University

15:30 16:00 (JST) Video session #1

17:00 19:00 (JST) 3rd session

Nano-scale approaches to physiological and pathological phenomena

Chair: Prof. Toshio ANDO/ NanoLSI

Speakers: Dr. Nobuo NODA/ Institute of Microbial Chemistry

Prof. Noriyuki KODERA/ NanoLSI

Assoc. Prof. Shinji WATANABE/ NanoLSI

Prof. Victor SHAHIN/ University of Mnster

19:00 19:30 (JST) Video session #2

Friday 27 November

10:00 12:00 (JST) 4th session

Imaging approaches to explore cancer biology

Chair: Prof. Masanobu OSHIMA/ NanoLSI/CRI

Speakers: Asst. Prof. Keehoon JUNG/Seoul National University College of Medicine

Prof. Takeshi IMAMURA/ Ehime University

Asst. Prof. Ann-Marie CHACKO/ Duke-NUS Medical School

Prof. Masanobu OSHIMA/ NanoLSI/CRI

12:00 12:05 (JST) Closing remarks

Further information

About WPI nanoLSI Kanazawa University Hiroe YonedaVice Director of Public AffairsWPI Nano Life Science Institute (WPI-NanoLSI)Kanazawa UniversityKakuma-machi, Kanazawa 920-1192, JapanEmail: nanolsi-office@adm.kanazawa-u.ac.jpTel: +81 (76) 234-4550

About Nano Life Science Institute (WPI-NanoLSI)

https://nanolsi.kanazawa-u.ac.jp/en/

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

SOURCE Kanazawa University

See original here:
Kanazawa University research: The Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University is organizing the 4th NanoLSI Symposium on 26 and...

Nordic Nanovector ASA: Results for the Third Quarter 2020 – PRNewswire

OSLO, Norway, Nov. 19, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's management team will take place today in Oslo at 08.30 CET, see details below. A link to the webcast and the presentation is available from the company's homepage (www.nordicnanovector.com).

Lars Nieba, Interim CEO of Nordic Nanovector, said: "Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. Generating these data will require us to successfully navigate the latest challenges of increased COVID-19 restrictions. We remain confident in our ability to achieve this goal, aided by the protocol amendments, the possibility to reduce the patient sample, and all the other measures we are actively implementing to drive patient recruitment into PARADIGME."

Q3'2020 Highlights

Events after Q3'2020

Financial Highlights

(Figures in brackets = same period 2019 unless otherwise stated)

Outlook

The company continues to target the readout of three-month top line data from PARADIGME in H2'2021. Approval of protocol amendments is proceeding as planned and completed in the best-recruiting countries, and other initiatives to increase the rate of enrolment are underway. The company also targets the readout of three-month top line data from the second cohort of the Archer-1 trial in H1'2021.

However, the impact of the COVID-19 pandemic on patient recruitment has worsened in light of the emergence of a second wave resulting in severe travel restrictions being implemented in the various countries where we are executing our clinical studies. These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. Several proactive actions have been taken to minimize the impact of these travel restrictions which could blunt further delays in completing enrolment and delivering preliminary results as targeted.

The company has taken steps to conserve cash and following the recent successful private placement, Nordic Nanovector has a cash runway that extends into Q3'2021.

Despite the challenging times, the many positive actions the company has made in the last nine months have improved the prospects of delivering pivotal results from PARADIGME in H2'2021.

The company continues to believe that, if positive, these trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin as a highly promising new targeted therapy that can address the unmet needs of R/R FL patients.

Presentation and live webcast Q3 2020 results A presentation and live webcast by Nordic Nanovector's management team will take place today at 8:30 am CET.

The webcast can be accessed from http://www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation is available at http://www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: [emailprotected]

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

Tel: +44 203 926 8535

Email: [emailprotected]

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Further information can be found at http://www.nordicnanovector.com .

Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--results-for-the-third-quarter-2020,c3239830

The following files are available for download:

SOURCE Nordic Nanovector

Read more:
Nordic Nanovector ASA: Results for the Third Quarter 2020 - PRNewswire

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer – BioSpace

Nov. 17, 2020 07:00 UTC

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205 the Company) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the United States Food and Drug Administration (FDA) has provided Safe to Proceed notifications for two additional trials in its ongoing clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson). These trials were co-developed with Nanobiotix and MD Anderson is the sponsor and executor.

Significant Unmet Needs and Opportunity in Cancer Immunotherapy

Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. However, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). These barriers present a significant unmet need to improve the efficacy ICIs and expand their potentially curative benefits to more patients with advanced cancers.

Combining ICIs with radiation therapy is emerging as a valuable strategy to prime an immune response and thereby increase the response rate, however the efficacy of radiation therapy is limited by toxicities related to the exposure of healthy tissues.

NBTXR3 is injected one time, directly into solid tumors. The product candidate is designed to increase the energy deposit from radiation therapy within the target tumor and subsequently increase the tumor-killing effect without increasing toxicity in surrounding healthy tissue. Pre-clinical and clinical data also suggest that NBTXR3 activated by radiation therapy can prime the immune system, creating an anti-tumor immune response that produces both local and systemic effects.

A Phase II Study of NBTXR3 Activated by Radiation and Combined with Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Limited PD-L1 Expression or Refractory to PD-1 Blockade

This MD Anderson trial is an open label, two cohort, non-randomized phase II study. The primary objective of the study is to evaluate tumor response of NBTXR3 activated by radiation therapy in combination with pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

The population includes patients with inoperable R/M HNSCC of the oropharynx, oral cavity, hypopharynx, larynx or neck. Patients could be anti-PD-1/L1 nave or refractory. Up to 60 patients may be treated, with up to 40 in the first cohort and up to 20 in the second cohort. The first cohort will include anti-PD-1/L1 nave patients with a combined positive score (CPS) between greater than or equal to 1% and less than 20%. The second cohort will include anti-PD-1/L1 refractory patients irrespective of PD-L1 expression.

A Phase II Study of Reirradiation with NBTXR3 in Patients with Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma

This MD Anderson trial is an open label, two cohort, non-randomized phase II study. The primary objectives of the study are: (i) to estimate progression-free survival (PFS) and the early clinical benefit in patients treated with NBTXR3 activated by SBRT re-irradiation, with concurrent pembrolizumab; (ii) to assess the safety profile and estimate the early clinical benefit of NBTXR3 activated by a reduced dose of IMRT or IMPT re-irradiation with concurrent pembrolizumab.

The population includes patients with inoperable, locoregional recurrent head and neck squamous cell carcinoma (HNSCC) or second primary HNSCC, previously treated with definitive radiation therapy and without radiographic evidence of metastases. Patients could be anti-PD-1/L1 nave or non-responders. Up to 80 patients may be treated, with up to 60 in the SBRT cohort and up to 20 in the IMRT/IMPT cohort.

***

About NBTXR3 NBTXR3 is a novel, potentially first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The primary mode of action (MoA) of NBTXR3 is designed to generate increased cellular destruction when activated by radiation therapy without increasing damage to healthy tissues. Subsequently, this cellular destruction also triggers an adaptive immune response.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.

Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.

About NANOBIOTIX: http://www.nanobiotix.com Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005910/en/

Go here to see the original:
Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer - BioSpace

Brigham and Womens researchers unveil cutting-edge innovation in virtual showcase – Boston Herald

Researchers from Brigham and Womens Hospital unveiled an array of cutting-edge medical technology in a Thursday virtual showcase that included a bedside teddy bear powered by artificial intelligence and a nasal spray that can prevent the spread of viruses.

The Discover Brigham event united doctors and scientists from all corners of the medical community to share the latest research and development of ideas and products that can shape the health care industry.

One such development is a nasal spray that can prevent the transmission of respiratory viruses by capturing and killing the inhaled aerosols in the nasal cavity.

In addition to containing the virus, the components of the formulation are also able to deactivate the virus within a few minutes of capture, said John Joseph, BWH postdoctoral fellow in the Center for Nanomedicine.

The pocket-sized spray coats the nasal cavity for up to four hours without irritation or sensory impairment, and can be used as a barrier when masks arent feasible such as while eating and drinking, Joseph said during Thursdays virtual demo. Researchers expect to test the spray against COVID-19 soon.

The spray is drug free, and will be cleared via mucus and expelled from the body through digestion three to four hours after use.

Our strategy has been designed in such a way that it can be easily integrated into daily life, Joseph said, adding that the product would play an especially important role in the context of the current and future pandemics.

On the softer side of the presentations sat Briggie, a plush teddy bear toy with the power of artificial intelligence that can ask patients about their pain level and respond to their requests.

Briggie has activating buttons, LED lights, a microcomputer, a microphone and a smart speaker to interact with patients, but it isnt like other smart technology.

It doesnt work like Alexa or Siri, it doesnt listen all the time, said Dr. Samir Tulebaev, Brigham associate physician.

Instead, Briggie is activated every hour, or whenever you need it, to ask about four key things pain, positioning, personal comfort and toileting.

Hello, my name is Briggie. I am an artificial intelligence nursing assistant. I will be asking about your pain every hour. I will send a text message to your nurse if you need any help, Briggie said during the demo.

When the patient is discharged from the hospital, they get to take the Briggie plush toy home with them.

Other innovations presented Thursday included artificial intelligence solutions to maintain stable vital signs during Cesarean delivery, an injection molded prototype N95 respirator for health care workers and many others.

Original post:
Brigham and Womens researchers unveil cutting-edge innovation in virtual showcase - Boston Herald

Antibacterial Properties of OsteoFab PEKK Implants Defined in New Research, Outperforming PEEK and Titanium – PR Web

We have been continually impressed with the strong bacteria resistance and pro-bone cell responses of OPMs PEKK samples, said Dr. Thomas Webster of Northeastern University. All resulting from optimal surface properties without resorting to the use of antibiotics or the release of growth factors

SOUTH WINDSOR, Conn. (PRWEB) November 18, 2020

Oxford Performance Materials, Inc. (OPM), an industry leader in advanced materials science and high performance additive manufacturing (HPAM), today announced additional results of an ongoing scientific study analyzing the antibacterial properties of 3D printed PEKK (poly-ether-ketone-ketone). These new results definitively establish a mechanism of action for how 3D printed PEKK exhibits inherent antibacterial characteristics, further confirming PEKKs role in combatting implant infections. In a continued partnership with Dr. Thomas Webster of Northeastern University, this research builds upon a September 2017 study(1) where samples produced by OPMs proprietary OsteoFab process demonstrated for the first time the promise that nanostructured PEKK has for numerous anti-infection orthopedic implant applications.

In a second set of experiments conducted by Dr. Webster in December 2019, it was determined that 3D printed PEKK demonstrated significant reductions for all bacteria colonization(2) when measured via colony forming units, crystal violet staining, and live/dead assays. This was true for all tested bacteria strains, which included S. epidermidis, P. aeruginosa, and MRSA, and all tested materials, as 3D printed PEKK significantly outperformed commercially available titanium and PEEK controls. This study was important for two primary reasons: it confirmed the results seen in the 2017 study(1) in the presence of titanium and PEEK controls and it raised the question of why PEKK is superior in this aspect, hinting that 3D printed PEKK may have a biologically optimal surface energy in the context of bacterial aversion.

In April of 2020, a follow-up study was conducted to determine the mechanisms of the antibacterial properties of 3D printed PEKK after 24 hours of culture, specifically examining protein adsorption and correlating that adsorption to bacteria response. Based on the test results(2), 3D printed PEKK exhibited a surface energy (35.7 mN/m) that was much closer to proteins lubricin (40 mN/m), mucin (42-46 mN/m), and casein (48 mN/m), which are all proteins known to reduce bacteria attachment and colonization naturally in vivo. When compared to the surface energies of PEEK (16.3 mN/m) and titanium (62.5 mN/m), it was evident 3D printed PEKK is optimal in terms of similarity to these naturally occurring proteins. As expected, the experiment showed greater protein adsorption of lubricin, mucin, and casein on PEKK in comparison to PEEK and titanium controls.

This greater protein adsorption was then correlated to greater bacteria inhibition of 3D printed PEKK compared to commercially available PEEK and titanium. For this portion of the study, samples were coated with lubricin, mucin, and casein, and bacteria attachment was characterized using colony forming unit counts, crystal violet staining, and live/dead assays. All results correlated the increased protein adsorption to decreased bacteria colonization for S. epidermidis, P. aeruginosa, and MRSA, again compared to PEEK and titanium controls.

This finding is extremely important as it provides objective evidence explaining why OPMs 3D printed PEKK exhibits inherent antibacterial effects. We have been continually impressed with the strong bacteria resistance and pro-bone cell responses of OPMs PEKK samples, said Dr. Webster. All resulting from optimal surface properties without resorting to the use of antibiotics or the release of growth factors, as our studies have shown. Equally significant are the implications of lubricin adsorption onto 3D printed PEKK, in terms of future joint and cartilage applications of the OsteoFab technology platform. Lubricin is a naturally occurring protein that is secreted in synovial joints; it coats surrounding cartilage and contributes to the overall integrity of the joint. With demonstrated adhesion to 3D printed PEKK, new devices could provide even more benefits in an increasing number of orthopedic applications.

The antibacterial attributes of 3D printed PEKK are significant since they address a key area of growing concern in medicine orthopedic implant infections. 3D printed PEKKs antibacterial properties, as detailed in this new study, will provide another important layer of differentiation for the performance of OsteoFab medical devices in the marketplace. Results from these experiments will be available in a forthcoming publication.

About Oxford Performance Materials, Inc.

Oxford Performance Materials, Inc. was founded in 2000 to exploit and commercialize the worlds highest performing thermoplastic, PEKK (poly-ether-ketone-ketone). OPMs Materials business has developed a range of proprietary, patented technologies for the synthesis and modification of a range of PAEK polymers that are sold under its OXPEKK brand for biomedical and industrial applications. The Company is a pioneer in 3D printing. OPM Biomedicals OsteoFab technology is in commercial production in numerous orthopedic implant applications, including cranial, facial, spinal, and sports medicine devices. OPM is the first and only company to receive FDA 510(k) clearance to manufacture 3D printed, patient-specific polymeric implants, and the company has six 510(k) clearances in its portfolio. OPM Industrial produces 3D printed OXFAB production parts for highly demanding applications in the energy, transportation, and semiconductor markets. OXFAB structures offer significant weight, cost, and time-to-market reductions that are defined in a set of specified performance attributes in the exhaustive OPM B-Basis database, developed in conjunction with NASA. For more information, please visit: http://www.oxfordpm.com

References

Antibacterial Properties of PEKK for Orthopedic Applications, International Journal of Nanomedicine, Dovepress 15-Sep-2017, Mian Wang, Garima Bhardwaj (Department of Chemical Engineering, Northeastern University, Boston MA) and Thomas J. Webster (Department of Chemical Engineering, Northeastern University, Boston MA and Wenzhou Institute of Biomaterials and Engineering, Wenzhou Medical University, Wenzhou, China). The full study by Mian Wang, et al. may be viewed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592909/

2. https://oxfordpm.com/uploads/files/OPM-T._Webster_AM_Med_Summit_19Oct2020_website.pdf?v=1605303394194

Company Contact: Bernie Plishtin Oxford Performance Materials 860-656-9446 bplishtin@oxfordpm.com

Share article on social media or email:

Originally posted here:
Antibacterial Properties of OsteoFab PEKK Implants Defined in New Research, Outperforming PEEK and Titanium - PR Web

Messenger RNA the Therapy of the Future – Newswise

With two companies leading the way in development of an mRNA (messenger RNA) vaccine to ward off COVID-19, one Houston Methodist physician researcher sees it as the first step for what has the potential to become the therapy of the future for all types of diseases. John Cooke, MD, PhD, director of the Research Institutes RNA therapeutics program, says mRNA is basically writing biological code to tell our bodies what proteins to make. Scientists need only the genomic sequence of the virus to come up with strategies to intervene.

Most vaccines today are still viral vaccines they are inactivated virus, so its potentially infectious and you have to have virus on hand, Cooke said. With mRNA, youre just writing code which is going to tell the cell to make a viral protein one part of a viral protein to stimulate an immune response. And, heres the wonderful thing, you dont even need the virusin hand, just its DNA code. His team is working with Houston Methodists nanomedicine team to develop better delivery options for mRNA, and he sees its potential in many fields: cancer, cardiovascular disease, liver disease, other infectious diseases and even rejuvenation.

Dr. John Cooke is available for interviews to discuss the process and promise of mRNA technology.

More:
Messenger RNA the Therapy of the Future - Newswise

SHAREHOLDER ALERT: WeissLaw LLP Reminds WTRE, TOTA, HCAC, and OAC Shareholders About Its Ongoing Investigations – PRNewswire

NEW YORK, Nov. 16, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212)682-3025(888) 593-4771[emailprotected]

Watford Holdings Ltd. (NASDAQ: WTRE)

WeissLaw LLPis investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Watford Holdings Ltd. (NASDAQ: WTRE) in connection withthe proposed acquisition of the company by Arch Capital Group Ltd. ("ACGL"). Under the terms of the acquisition agreement, WTRE shareholders will be entitled to receive $31.10 in cash for each share of WTRE common stock that they own. If you own WTRE shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/wtre/

Tottenham Acquisition I Limited (NASDAQ: TOTA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors ofTottenham Acquisition I Limited (NASDAQ: TOTA) in connection with the company's proposed merger with privately-held clinical-stage biopharmaceutical company, Clene Nanomedicine, Inc. ("Clene"). Under the terms of the merger agreement, TOTA will acquire Clene through a reverse merger that will result in Clene becoming a public company listed on the Nasdaq Capital Market. The proposed transaction values Clene at $542.5 million. If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/tottenham-acquisition-i-limited/

Hennessy Capital Acquisition Corp. IV(NASDAQ: HCAC)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hennessy Capital Acquisition Corp. IV(NASDAQ: HCAC)in connection with HCAC's merger with privately-held Canoo Holdings Ltd. ("Canoo"). Under the terms of the proposed transaction, HCAC will acquire Canoo through a reverse merger that will result in Canoo becoming a publicly-listed company. If you own HCAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/hennessy-capital-acquisition-corp-iv/

Oaktree Acquisition Corp. (NYSE: OAC)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oaktree Acquisition Corp. (NYSE: OAC) in connection with the company's proposed merger with privately-held telehealth company Hims, Inc. ("Hims"). Under the terms of the merger agreement, OAC will acquire Hims through a reverse merger that will result in Hims becoming a publicly-listed company on the New York Stock Exchange under the new ticker symbol "HIMS." If you own OAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/oac/

SOURCE WeissLaw LLP

http://weisslawllp.com

Originally posted here:
SHAREHOLDER ALERT: WeissLaw LLP Reminds WTRE, TOTA, HCAC, and OAC Shareholders About Its Ongoing Investigations - PRNewswire

Ra Medical Systems to Feature the Pharos Optimized Excimer Laser at the Virtual New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium…

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces it will feature the Pharos excimer laser at the New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium 2020 Virtual Meeting being held November 21, 2020.

We are delighted to showcase our Pharos excimer laser at this conference, said Will McGuire, Ra Medical Systems CEO. Pharos provides topical treatment of common skin disorders including psoriasis, vitiligo, atopic dermatitis and leukoderma and is a lower cost and safe alternative to immunosuppressive agents. During the pandemic, Pharos may play a particularly valuable role for patients who may be otherwise immunocompromised.

About the New Frontiers in Cosmetic Medicine & Medical Dermatology Conference

New Frontiers in Cosmetic Medicine Symposium will deal with the latest developments in cosmetic dermatology, cosmetic medicine, and anti-aging medicine. It is designed for an audience of physicians, physician assistants, nurses and nurse practitioners who work under the direct supervision of dermatologists, facial plastic surgeons, oculoplastic surgeons, and plastic surgeons, and commonly assist with cosmetic surgery and medicine. More information is available at https://www.cosmeticfrontiers.com/.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017 the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medicals core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medicals future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as may, will, should, expects, plans, anticipates, could, intends, target, projects, contemplates, believes, estimates, predicts, potential or continue or the negative of these words or other similar terms or expressions that concern Ra Medicals future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and potential outcome of the DABRA atherectomy clinical study. Ra Medicals expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks associated with acceptance of DABRA and Pharos and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products or product enhancements; clinical and statistical verification of the benefits achieved via the use of Ra Medicals products; the results from our clinical trials, which may not support intended indications or may require Ra Medical to conduct additional clinical trials or modify ongoing clinical trials; challenges related to commencement, patient enrollment, completion, and analysis of clinical trials; Ra Medicals ability to manage operating expenses; Ra Medicals ability to effectively manage inventory; Ra Medicals ability to recruit and retain management and key personnel; Ra Medicals need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medicals industry; the impact of rapid technological change; costs and adverse results in any ongoing or future legal proceedings; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medicals news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medicals business and operating results is contained in Ra Medicals Annual Report on Form 10-K for the year ended December 31, 2020 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material information to the public about the company through a variety of means, including our website (www.ramed.com), our investor relations website (https://ir.ramed.com/), press releases, SEC filings, and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Read more:
Ra Medical Systems to Feature the Pharos Optimized Excimer Laser at the Virtual New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium...

Five anti-aging foods — and some that age – Richmond Register

You don't need that expensive face cream to look younger, just focus on your diet to help preserve your youthful appearance.

Here are some of the best anti-aging foods and a few to limit when it comes to maintaining a healthy, good looking body.

Best anti-aging foods

n Cheese

Ever wondered why some restaurants offer cheese as a post-meal desert? One reason is because a little cheddar can counteract the acid left behind after a meal. Not only that, calcium helps build strong teeth. So nibbling on cheese after dinner can bring some bling to your pearly whites.

n Tomatoes

These healthy fruits are loaded with lycopene, an antioxidant with natural sunscreen properties. Tomato paste is a good source of lycopene, so adding it to your pasta sauce or as a pizza topping can make a difference to your skin.

n Salmon

A superfood when it comes to your body, the essential omega-3 fats are great for healthy and nourished skin too. Salmon contains anti-oxidants such as selenium and vitamin E that protect against free radicals that can have damaging and aging effects on the skin. Nuts, seeds and avocados are also fantastic for a healthy complexion.

n Watermelon

Even though watermelon is 93 percent water, it's still packed with vitamins and anti-oxidants to help ward off premature aging. Watermelon also contains vitamin A that is linked to helping treat acne, according to a 2015 study in Medical Archives.

n Olive Oil

The monounsaturated fat and anti-oxidants found in olive oil provide numerous health benefits, including heart function, improved memory, reduced inflammation and many others, according to a paper published in the March 2018 issue of the International Journal of Molecular Science. Not only that, olive oil helps keep skin moisturized and protected from damage.

Worst anti-aging foods

n Sugar

Sweets aren't just bad for your teeth, they age your skin too. Collagen production naturally decreases as you get older, but consuming excess sugar speeds up the process.

A study in the Clinics in Dermatology journal highlighted just how sugar is thought to be harmful to your skin. Glucose and fructose, the sugar molecules, link the amino acids in the collagen and elastin that support the skin, producing advanced glycation end products (AGEs).

These AGEs accelerate the process. Research has also found a link between eating a high-glycemic diet (sugar foods) and acne, although the research doesn't show causation

n Salt

Clearly a flavor enhancer, salt is a favorite ingredient in lots of dishes. But too much salt (more than 2,300 milligrams a day) not only increases blood pressure, it can be bad for your skin too.

In a 2019 study published in the journal Science Translational Medicine, skin lesions on people with eczema were found to have elevated levels of sodium chloride (salt), although causation could not be proved.

n Alcohol

Drinking more than the recommended daily amount of alcohol (one drink for women, two drinks for men) can cause dehydration, making your skin look dry and withered. Excess alcohol can also cause inflammation, leading to a myriad of problems such as acne, breakouts, and disrupted sleep.

Poor sleep quality then leads to dark circles under the eyes, wrinkles and sagging skin.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

Read this article:
Five anti-aging foods -- and some that age - Richmond Register

CT team developing COVID drug to reverse aging … really – CT Insider

The older you are, the more likely your COVID-19 infection will be more severe, and even fatal. Of the nearly 5,000 COVID-related deaths in Connecticut to date, 81 percent are people over 70 years old.

But what if you could turn back the clock? A team of researchers at UConn are working on ways to literally reverse the effects of aging, as a way to mitigate the severity of a COVID infection.

The goal here is not to erase aging, but rather were testing interventions that are designed to slow the rate of biological aging, and therefore help prevent severe COVID, according to George Kuchel, director of UConns Center on Aging and chief of geriatric medicine at UConn Health.

One drug in particular, called compound RTB101, can theoretically not only slow aging but boost the immune response, helping the body and any potential vaccines do their jobs better.

Thats important because, as Kuchel said, these vaccines dont work as well on older adults.

Even if the vaccine turns out to be as effective, as the initial studies suggest, theres a very strong likelihood that its going to be less effective in older adults, he said. These kinds of approaches are going to be important as additional therapies to the vaccine, for the vaccine alone is not going to be sufficient.

Another weakness of any potential vaccine is their specificity. The COVID-19 pandemic may be contained, but the virus could mutate, or another virus might emerge.

At some point, were going to be done with COVID-19, hopefully, Kuchel said. But I think we all agree that there could very well be another COVID, whether its COVID-21, 22, whatever, or another pathogen out there, that we dont even know about yet. And if older adults are more vulnerable to get this and to die from it, then we believe this approach will be helpful irrespective of what the infection is.

The compound known as RTB101 doesnt actually make you younger. Theres a difference, Kuchel explained, between chronological age how many years you have been alive and biological age.

Whereas biological aging is an effort to capture the rate of aging, how fast somebody ages, Kuchel said. As you can imagine, you could have two people who are both 70 years old, and one could have a biological age which would be younger than most 70-year-olds, and another one who has a biological age that would be older than most 70-year-olds.

RTB101 targets the biological pathways that control the aging process, the so-called mTOR pathway, for example.

Early versions of the compound have been studied for decades at Connecticuts Jackson Labs and elsewhere and have been shown to slow aging in mice.

While inhibiting the natural processes that lead to biological aging, the compound also boosts the bodys ability to fight disease.

There are a lot of genes that are involved in our ability to fend off viral infections, Kuchel said. There are these inflammatory molecules called interferon gamma. That whole family of molecules are very important to our ability to fend off infection, particularly viral infections. What this compound does is it boosts those responses. So it down-regulates mTOR and it up regulates the interferon gamma responses.

In a sense, it kind of resets the body to behave the way it would have at a younger age, and to boost immune responses, Kuchel said.

The work on RTB101 is being funded by the National Institutes for Health and the first step which the team at UConn is currently recruiting subjects for is a small-scale feasibility study involving people over the age of 65 who have either been recently diagnosed with a COVID-19 infection or who lives with someone diagnosed with COVID in the last few days.

Were in a very tight timeline, Kuchel said. We need to do this in the next two months.

But dont expect your doctor to prescribe an anti-aging drug any time soon.

After the feasibility study will come a large-scale, multi-site clinical trial. Only then will Kuchel and his team seek FDA approval.

I know that sometimes the progress of science seems maddeningly slow. But unfortunately, its the only way we can show that it works, Kuchel said. In terms of this being available at physicians offices, its not going to be within the next year or two. This is going to take some time.

But, again, this sort of research could be important, Kuchel said, because it is not a therapy to treat or prevent any specific disease.

We believe that will be transformative not only for the current COVID pandemic, but for future pandemics, future infections, which we know are going to happen, he said. We know that future infections will happen, we know that older adults will be more vulnerable. Thats absolutely clear. The only thing we dont know is what the pathogen will be. With this approach, the argument can be made that we dont need to know what that pathogen is because were not targeting the pathogen, were targeting the person.

Follow this link:
CT team developing COVID drug to reverse aging ... really - CT Insider

Ageing in humans reversed by hyperbaric oxygen therapy: Israel study – The CEO Magazine

Ageing, which happens over time in humans, has been biologically reversed by hyperbaric oxygen therapy, according to new research published in the journal Aging.

Scientists, led by Yafit Hachmo, from the Research and Development Unit, Shamir Medical Center, Tzrifin, Israel, turned back the human clock for 35 adults aged 64 and older by reversing two key areas of the body thought responsible for the frailty and ill-health that comes with growing older. Protective caps at the ends of chromosomes, known as telomeres, shorten, causing DNA to become damaged and cells to stop replicating as people age. At the same time, senescent cells build up in the body, preventing regeneration.

Increasing telomere length and getting rid of senescent cells is the focus of anti-ageing research, with drugs being developed to target those areas, The Telegraph reported.

The 35 patients were repeatedly given pure oxygen in a hyperbaric chamber, which increased the length of their telomeres by 20%, a feat that has never been achieved before.

Scientists said the growth may mean that the telomeres of trial participants were now as long as they had been 25 years earlier.

The therapy also reduced senescent cells by up to 37%, enabling new healthy cells to regrow. Animal studies have shown that removing senescent cells extends remaining life by more than 33%.

Since telomere shortening is considered the Holy Grail of the biology of ageing, many pharmacological and environmental interventions are being extensively explored in the hopes of enabling telomere elongation, said one of the scientists involved in the research, Professor Shai Efrati, Director of the Sagol Center at Shamir Medical Center.

The significant improvement of telomere length shown during and after these unique protocols provides the scientific community with a new foundation of understanding that ageing can indeed be targeted and reversed at the basic cellular-biological level.

Scientists believe ageing itself is responsible for diseases such as Alzheimers, Parkinsons, arthritis, cancer, heart disease and diabetes.

It is known that obesity, smoking, lack of physical activity, vitamin deficiency and inflammation can speed up the shortening of telomeres, demonstrating that they have a major impact on the length of a life.

The 35 participants did not undergo any lifestyle, diet or medication adjustments. Each patient was placed in a hyperbaric chamber for 90 minutes for five days a week over three months while breathing 100% oxygen through a mask.

The pressurised chamber allows more oxygen to be dissolved into the tissues and mimics a state of hypoxia, or oxygen shortage, which is known to have regenerating effects.

Previous trials have shown that eating a healthy diet can preserve telomere length, while high-intensity training for six months has been proven to lengthen telomeres by up to 5%.

The Israeli team has also previously demonstrated that the pressurised oxygen therapy can improve cognitive decline.

Until now, interventions such as lifestyle modifications and intense exercise were shown to have some inhibition effect on the expected telomere length shortening, said Dr Amir Hadanny, Chief Medical Research Officer of the Sagol Center for Hyperbaric Medicine and Research.

However, what is remarkable to note in our study is that, in just three months of therapy, we were able to achieve such significant telomere elongation at rates far beyond any of the current available interventions or lifestyle modifications.

With this pioneering study, we have opened a door for further research on the prolonged cellular impact of the therapy to reverse the ageing process. After dedicating our research to exploring its impact on the areas of brain functionality and age-related cognitive decline, we have now uncovered, for the first time in humans, biological effects at the cellular level in healthy ageing adults.

The researchers pointed out that the study has several limitations and strengths to consider. First, the limited sample size has to be taken into account. Second, the lack of a control group.

However, the study suggests impressive results on telomeres and senescent cell clearance, which werent observed in other interventions, said the research paper.

Read the original:
Ageing in humans reversed by hyperbaric oxygen therapy: Israel study - The CEO Magazine

Rally in support of mask mandate and Sioux Falls medical workers – KELOLAND.com

The mild weather days are nice to enjoy, but we all know real winter cold isn't too far awayNews / 10 hours ago

The forecast this week is showing another round of very mild weather moving into KELOLANDNews / 1 day ago

The warm weather this week is a continuation of the temperatures earlier this monthNews / 2 days ago

KELOLAND Live Doppler HD Storm Center Winter Weather Special 2020News / 6 days ago

Weather outlook: Temperature swings throughout month of NovemberNews / 5 days ago

Our already chilly nights have become a little bit colder latelyNews / 6 days ago

Winter gave a nice looking landscape to southeast KELOLAND this morningNews / 1 week ago

Taking a look at last week's record high tempsNews / 1 week ago

Warm first week of November breaks over 100-year recordNews / 2 weeks ago

Much colder air arrives next weekNews / 2 weeks ago

Another prolonged stretch of dry weather will stick around in KELOLANDNews / 2 weeks ago

Warm weather in the forecast could set new recordsNews / 2 weeks ago

See the original post:
Rally in support of mask mandate and Sioux Falls medical workers - KELOLAND.com

Device Reads Paralyzed People’s Thought Through Their Veins – Anti Aging News

Synchron recently announced the publication of a first-in-human study demonstrating the successful use of their device called Stentrode which is a brain-computer interface neuroprosthesis. The brain implant that is inserted in the jugular allows ALS patients to type with their minds.

Synchrons CEO, Thomas Oxley, MD, Ph.D., describes the implant as Bluetooth for the brain. The big difference between what we have done with what previous approaches have done is that we do not put any needles into the brain or on top of the brain. The device stays inside the blood vessel.

The study findings published in the Journal of NeuroInterventions Surgery specifically show the devices ability to enable patients with severe paralysis to resume daily tasks such as texting, emailing, shopping and banking online all through direct though without the need for open brain surgery.

This study is the first to demonstrate that a BCI that has been transplanted via patient blood vessels is able to restore the transmission of brain impulses out of the body wirelessly; patients successfully used their impulses to control digital devices without using a touchscreen, mouse, keyboard or voice-activated technology.

This is a breakthrough moment for the field of brain-computer interfaces. We are excited to report that we have delivered a fully implantable, take home, wireless technology that does not require open brain surgery, which functions to restore freedoms for people with severe disability, said Thomas Oxley MD Ph.D., founding CEO, Synchron. Seeing these first heroic patients resume important daily tasks that had become impossible, such as using personal devices to connect with loved ones, confirms our belief that the Stentrode will one day be able to help millions of people with paralysis.

Using the Stentrode neuroprosthesis device patients controlled the Microsoft Windows 10 operating system, in combination with an eye tracker for cursor navigation without a mouse or keyboard. Patients undertook machine learning assisted training to control multiple mouse click actions, and the first 2 patients were able to achieve an average click accuracy of 92 and 93% with typing speeds of 14 and 20 characters per minute with predictive text disabled. The device was used to resume daily tasks independently following implantation and training to commence unsupervised home use of the system from day 86 and 71.

Using the Stentrode has been life-altering, said Graham Felstead, the first patient enrolled in the first Stentrode clinical study and the first person to have any BCI implanted via the blood vessels. The device has allowed me to be productive again, including shopping, banking, and delegating tasks among the Rotary Club members with whom I volunteer. Its incredible to gain this level of independence back. By using the Stentrode, Graham was able to achieve his goals of remotely contacting his spouse, increasing his autonomy and reducing her burden of care. He was able to maintain contact with other family members, medical professionals and people in his community. Graham, a 75-year-old man living at home with his wife, has experienced severe paralysis due to amyotrophic lateral sclerosis (ALS), and received the Stentrode implant in August 2019. He continues to use it today.

It is truly amazing, and very rewarding, to see the participants use the Stentrode to control a computer with their minds, independently and at home, said Nicholas Opie, associate professor and co-head of the vascular bionics laboratory at the University of Melbourne and founding CTO of Synchron. The trial participants have been fantastic, and my colleagues and I are truly honored to make a difference in their lives. I hope others are inspired by their success.

The second participant, Philip OKeefe, a 60-year-old man with ALS, working part-time and living at home with his wife and two children, was able to control computer devices to conduct work-related tasks and other independent activities after receiving the Stentrode in April 2020. Functional impairment to his fingers, elbows, and shoulders had previously inhibited his ability to engage in these efforts.

While the Stentrode is a completely novel concept and design, the procedure to implant it draws upon techniques that I use on a daily basis and which have become routine in our industry. The Stentrode technology exemplifies the progress and potential of neurointervention departments to deliver new therapies to patients, said Professor Peter Mitchell, Director of Neurointervention, The Royal Melbourne Hospital, a pioneering neurointerventionalist who performed the first clinical implantations of the Stentrode device. The intricacies of the brain have always fascinated me and enabling a patient with paralysis to continue to use their mind in a productive way is immensely rewarding.

This device is small and flexible enough to safely pass through curving blood vessels, the implantation procedures are similar to that of a pacemaker and does not require open brain surgery. This may reduce the risk of brain tissue inflammation and rejection of the device which has been an issue for devices in the past using techniques that require direct brain penetration.

The device is delivered into the jugular vein, using a catheter to thread the device upward until it is adjacent to the motor cortex. Once implanted the device is able to pick up nearby brain activity using tiny electrodes that dot its surface. A second device embedded into the patients chest transmits data wirelessly to a computer or other smart device that is running the machine learning software which in turn converts that information into computer commands and functions.

Other approaches to brain-computer interfaces have been focused on high data rates, which create technical barriers to clinical translation. Synchron has focused on building a product that measurably improves patients lives. Our first-to-market product will focus on smart device control using brain impulses, without the need for the use of the hands. This alone has potential to address an unmet market need in 30 million patients in advanced economies, added Oxley.

The US FDA granted Stentrode Breakthrough Device designation, and the safety and efficacy data from this feasibility study will be used to finalize the protocols for a future FDA approval trial that will eventually guide the evaluation of the device for American marketing approval.

The neurovascular bioelectronic medicine company presented preliminary data on the first patient at the Society of NeuroInterventional Surgery Annual Meeting In August 2020, and the long term safety as well as ability to pick up specific electrical frequencies emitted by the brain was established by preclinical studies that were published in Nature Biotechnology, Nature Biomedical Engineering and the Journal of Neurosurgery.

Eventually, the company plans to use this technology to help paralyzed patients control robotic limbs in order to provide them even more freedom and have an even bigger positive impact on the everyday lives of people who use it.

Visit link:
Device Reads Paralyzed People's Thought Through Their Veins - Anti Aging News

The Worldwide Industry for Aesthetic Fillers is Expected to Grow at a CAGR of 10.35% Between 2019 and 2028 – GlobeNewswire

Dublin, Nov. 13, 2020 (GLOBE NEWSWIRE) -- The "Global Aesthetic Filler Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.

According to this research report, the global market for aesthetic filler is expected to surge at a CAGR of 10.35% during the evaluated period of 2019-2028.

The growing demand for aesthetic fillers, a surge in healthcare expenditure, rising acceptance of tissue fillers, and a growing aging population are significant factors that augment the aesthetic filler market's progression worldwide. Additionally, the increasing number of men undergoing cosmetic procedures, along with growing awareness about cosmetic procedures, are creating multiple opportunities for the market's future.

However, the negative effect of unregistered practitioners, paired with the high cost of procedures, are significantly weighing down the aesthetic filler market.

The global aesthetic filler market covers the Asia-Pacific, Europe, North America, Latin America, and the Middle East and Africa regions.

The Asia-Pacific is expected to become the fastest-evolving market for aesthetic filler over the estimated period 2019-2028. In China, the younger population is mainly persuaded by westernized looks, which leads them to undergo cosmetic procedures. Among the various procedures, facelift and eyelid surgery, are the most common cosmetic procedures. Additionally, China has the highest number of cosmetic procedures, with growing male customers. The people between 20 and 40 are undergoing cosmetic surgeries, which is enhancing the demand for facial surgeries. This further augments the aesthetic filler market in China, thereby overall APAC region.

The key enterprises involved in the aesthetic filler market are Galderma Pharma SA, Laboratoires Vivacy SAS, Sculpt Luxury Dermal Fillers Ltd, Zhejiang Jingjia Medical Technology Co Ltd, Suneva Medical Inc, Teoxane, Bioxis Pharmaceuticals, Contura Ltd, Prollenium Medical Technologies, Anika Therapeutics Inc, Bioha Laboratories, Allergan, Merz Pharma, Sinclair Pharma, and Ipsen.

Allergen is a global pharmaceutical company that concentrates on manufacturing, and commercializing branded regenerative medicine, pharmaceutical device, surgical, and biologic products for patients. Its product portfolio comprises products for medical aesthetics and dermatology, women's health, and eye care, among others. The company has its headquarter in Ireland, with its operation across all regions.

Key Topics Covered:

1. Global Aesthetic Filler Market - Summary

2. Industry Outlook2.1. Market Definition2.2. Key Insights2.2.1. Increased Awareness About Anti-Aging Measures2.2.2. Increasing Popularity of Minimally Invasive and Non-Invasive Procedures2.3. Impact of COVID-19 on Aesthetic Filler Market2.4. Porter's Five Forces Analysis2.4.1. Threat of New Entrants2.4.2. Threat of Substitute2.4.3. Bargaining Power of Buyers2.4.4. Bargaining Power of Suppliers2.4.5. Threat of Competitive Rivalry2.5. Market Attractiveness Index2.6. Vendor Scorecard2.7. Market Drivers2.7.1. Growing Demand for Facial Aesthetics2.7.2. Rising Acceptance of Tissue Fillers2.7.3. Increasing Aging Population2.7.4. Increase in Healthcare Spending2.8. Market Restraints2.8.1. Negative Effect of Unregistered Practitioners2.8.2. High Cost of Procedure2.9. Market Opportunities2.9.1. Increasing Number of Men Undergoing Cosmetic Procedures and Awareness About Cosmetic Procedures2.9.2. Increase in Beauty Consciousness and Disposable Income2.9.3. Advancements in Facial Rejuvenation2.10. Market Challenges2.10.1. Challenges Arising from Reimbursement Issues, Social Stigma, and Rapidly Advancing Technologies2.10.2. Side Effects Associated with Dermal Fillers

3. Global Aesthetic Filler Market Outlook - by Product Type3.1. Wrinkle Relaxers3.2. Dermal Fillers3.2.1. Collagen3.2.2. Hyaluronic Acid3.2.3. Fat Injection3.2.4. Polylactic Acid3.2.5. Polymethyl Methacrylate Microspheres (Pmma)3.2.6. Calcium Hydroxylapatite

4. Global Aesthetic Filler Market Outlook - by Application4.1. Facial Line Correction4.2. Lip Treatment4.3. Face Lift4.4. Acne Scar Treatment4.5. Lipoatrophy Treatment4.6. Others

5. Global Aesthetic Filler Market - Regional Outlook5.1. North America5.2. Europe5.3. Asia-Pacific5.4. Latin America5.5. Middle East and Africa

6. Competitive Landscape6.1. Allergan (Acquired by Abbvie)6.2. Galderma Pharma Sa (Acquired by Eqt)6.3. Laboratoires Vivacy Sas6.4. Merz Pharma6.5. Sinclair Pharma6.6. Suneva Medical Inc6.7. Teoxane6.8. Anika Therapeutics Inc6.9. Bioha Laboratories6.10. Bioxis Pharmaceuticals6.11. Contura Ltd6.12. Prollenium Medical Technologies6.13. Zhejiang Jingjia Medical Technology Co Ltd6.14. Sculpt Luxury Dermal Fillers Ltd6.15. Ipsen

7. Methodology & Scope

For more information about this report visit https://www.researchandmarkets.com/r/v0qj9e

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more from the original source:
The Worldwide Industry for Aesthetic Fillers is Expected to Grow at a CAGR of 10.35% Between 2019 and 2028 - GlobeNewswire

Marie Stopes International name change will put a focus on the future of reproductive choice, CEO says – The World

Marie Stopes Internationalis one of the largest organizations in the world providing women's health care and family planning services. Recently, they announced that starting Tuesday, they are changing their name to MSI Reproductive Choices.

That's because their namesake, Marie Stopes, was a birth control pioneer in early 1900s England, but was also a supporter of eugenics, a now-discredited movement to improve the human race through selective reproduction.

Stopes opposed interracial marriage and advocated for the sterilization of people considered unfit for parenthood.

MSI said the change was a clear signal that we neither adhere to nor condone Stopes' views, who was also a womens rights campaigner andfounded Britains first birth control clinicknown as The Mother's Clinic, in London, in 1921.

The modern organization was founded in 1976 when Dr. Tim Black saved the financially struggling Marie Stopes clinic from closure. The organization now operates more than 600 clinics around the world.

Simon Cooke is the chief executive officerof MSI Reproductive Choices and joins The World's host Marco Werman,from London, to talk about the name change and the future of MSI in 37 countries around the world.

Related:How the US presidential election could impact women's health

Simon Cooke: Marie Stopes International, which is the organization we've just transitioned the name away from, was founded in 1976, by Dr. Tim Black. And we took the name of Marie Stopes because Tim Black took over The Mother's Clinic [the original Marie Stopes clinic] which is in central London. So, there's actually no direct connection to Marie Stopes, apart from the fact that we took over that particular clinic, which was very well-known in the UK as the first birth control clinic in England. Marie Stopes is a person who was born in 1880. She was certainly a woman of her time, an acknowledged family planning pioneer, an extraordinary woman in many ways. But as you say, she did have extreme views on eugenics, as many people did at the time. And we felt that those views were not really compatible with MSI's values and principles today and hence the need for the change of name.

Related:Activists in Kenya challenge abortion ban in court

It is right, yeah. I mean, we originally had a resolution from our board of trustees back in November 2019 to change the name because this is not a new topic for us. And we had been discussing it for some time. Obviously, with Black Lives Matter and the discussions that came up around that within our organization, with many people hearing some of Marie Stopes' views for the first time, we felt it was entirely the right time to make that decision. And at the same time, we're launching a new 10-year strategy, which obviously allows us to reposition ourselves to explain a little bit more about what we do in the name and to really put a focus on the future rather than continue to focus on the past.

To some extent, it hasn't really affected us because most of our work is done overseas, and we're in 37 countries where those connections are not really understood or known. And our work is very much focused on alleviating poverty and gender empowerment and gender equality, so really trying to focus on those with the greatest unmet need for contraception or safe abortion services. So, those connections are not made. Increasingly, though, in the UK, some of the Marie Stopes connections have come up again and again in the last three or four years, particularly, and mainly inside our own organization, among our staff, that they felt increasingly uncomfortable with the association and felt that there was an appropriate time to to make that disassociation. And therefore, we're very happy to have done that. The Black Lives Matter movement, clearly for us, was another matter of internal discussion that allowed us to make that decision. And we feel it was entirely right.

Related:From Burkina to Zimbabwe, US aid cuts squeeze family planning

No, I don't think so. I mean, it's come up surprisingly little. I mean, most people who fund us and who work with us understand that we were founded in 1976, and that we took over The Mother's Clinic, and that's the reason why we took the name. But beyond that, that the association really hasn't become an issue until quite recently and actually most notably in the US, because we have more of a presence in the US now as a fundraising organization to support our mission overseas. That was a problem for us as we tried to reach out to potential donors in the US who had never heard of it before. But at that point, I think the discussion became more pivotal and we felt that we needed to do something, to take action.

Our vision for 2030 is that no abortion will be unsafe and every individual will have access to contraception. And today, as I said, we operate in 37 countries. We provide 28,000 services a day. But there is a huge amount to be done because there are 230 million women and girls worldwide who have no access at all to contraception but want it. That is a need that needs to be met, we know how to do this and we know what it costs. We are going to use the new strategy really to define how to close that gap and how to make sure that every woman and every girl who wants access to contraception will be able to get it. The strategy is really to focus on choice, which is in the name reproductive choices and also to broaden services beyond just safe abortion and contraception to a range of services to support women and girls from their first period through menopause.

This interview has been edited and condensed for clarity. The Associated Press contributed to this report.

The rest is here:
Marie Stopes International name change will put a focus on the future of reproductive choice, CEO says - The World

Octopus-inspired robot can climb ladders and walls – Massive Science

Today, multinational pharmaceutical company Pfizer reported their mRNA-based vaccine candidate, BNT162b2, was more than 90 percent effective against SARS-CoV-2, based on early phase 3 clinical trial data.

The study enrolled 43,538 participants in six countries who were spilt into two groups: a group that was received the vaccine candidate, and a group that received a placebo treatment.

Since the start of the phase 3 trial on July 27th, 94 confirmed cases of COVID-19 have been reported in the study group. Fewer than 10 percent of those cases were from participants who had been given the vaccine candidate, and more than 90 percent of the cases were from the placebo group.

Pfizer reported no serious safety concerns with the vaccine, and that 42 percent of the trial participants had racially or ethnically diverse backgrounds. The second point is key, as BIPOC communities show higher rates of COVID-19 infection, hospitalization, and mortality than white, non-Hispanic communities.

The study will continue monitoring their participants until 164 confirmed cases of COVID-19 occur in the trial population to gain more accurate information about the vaccines efficacy.

How does it work?

The vaccine candidate contains genetic material from the virus called messenger RNA. As its name suggests, messenger RNA carries information between different parts of a cell, providing instructions like which proteins to make.

BNT162b2 uses messenger RNA that describes one of the spike proteins that stud the outer surface of SARS-CoV-2. Though human cells dont make spike proteins, they can still read viral messenger RNA and follow its instructions. When someone receives a dose of BNT162b2, their body responds by producing the spike protein, but only the spike protein, and no other part of the virus.

Since spike proteins arent normally found in human cells, their presence triggers the immune system, leading to a defensive response where the proteins are removed. Now that the immune systems had some practice, its ready for the real thing. If someone who was vaccinated against SARS-CoV-2 was exposed to the virus later on, their immune system is ready to react, and hopefully, fend off the virus.

Messenger RNA vaccines are relatively new on the scene, but have the potential to be safer and more effective than other vaccine types. There is no risk of getting COVID-19 from a vaccine, as the virus is never present in the body.

Hold on, there are some caveats

The Pfizer data is promising, but there are some barriers that will need to be dealt with should BNT162b2 see broad production and distribution.

The logistics are tricky, as the drug must be stored in a -80oC (-112 oF) freezer. This is standard equipment for biomedical research labs in universities and hospitals, but rare in doctors offices and pharmacies. This is a severe requirement even by the standards of vaccines. Inactivated flu vaccines can often be stored in a normal 2-8oC fridge, and even Moderna's similar mRNA vaccine only needs to be frozen at -20oC. Moderna's vaccine is also stable longer once thawed (that is to say that Pfizer's vaccine deteriorates faster once unfrozen), which would make administering it to a population a bit easier.

The vaccine also needs two doses. This means at least twice as much vaccine needs to be manufactured as a single dose treatment, assuming perfect compliance with vaccine scheduling. In their press release, Pfizer reported they expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Another issue with multi-dose vaccines is that not everyone can reliably get both doses, leading to inequality in vaccine access. For example, Black and Hispanic/Latinx adolescent girls are disproportionately prone to low HPV vaccination completion rates compared to white adolescent girls after adjusting for difference in socioeconomic status and insurance coverage. Solving vaccine access and completion issues will be key to high vaccination rates and creating herd immunity to COVID-19.

Though this is still much work to do (including the completion of the clinical trial), this announcement has been hailed as welcome news in the ongoing worldwide health crisis.

Read more:
Octopus-inspired robot can climb ladders and walls - Massive Science

Third Committee Approves 11 Drafts, among Them 4 Covering Women’s Rights, Omnibus Text on High Commissioner for Refugees Report, as Myriad Amendments…

GA/SHC/4310

In a day of intense action, the Third Committee (Social, Humanitarian and Cultural) approved 11 draft resolutions, including 4 on the broad theme of the advancement of women, which touched on the special needs of women and girls living in conflict-affected areas, complex humanitarian emergencies and terrorism.

Among them was a draft approved by a recorded vote of 170 in favour to none against, with 11 abstentions on preventing and eliminating all forms of violence against women and girls. By its terms, the Assembly would urge States to take effective action to eliminate all such violence and to address structural and underlying causes and risk factors.

Its passage weathered unyielding attempts to pass seven draft amendments, proposed by the Russian Federation, and three proposed by the United States, to address wording concerns. Each of the measures failed in recorded votes.

The representative of the Netherlands, presenting the draft resolution, highlighted the dramatic increase in violence against women and girls during the COVID19 pandemic. The draft expresses an unambiguous condemnation of violence, and presents a global compromise, based on agreed language. We all had to compromise, he said, rejecting the proposed amendments as hostile. Echoing those concerns, the United Kingdoms representative rejected the amendments, several of which sought to weaken language on sexual and reproductive rights. South Africas delegate likewise said the proposed amendments contradict the principle of multilateralism. Terms, such as sexual and reproductive health, were agreed upon in the 1990s. Meanwhile, Egypts representative expressed support for amendment L.59, stressing that the concept of intimate partner violence remains unclear and lacks an internationally agreed definition.

In other action, the Committee approved its omnibus draft resolution on the report of the Office of the United Nations High Commissioner for Refugees (UNHCR), by a recorded vote of 174 in favour to none against, with 7 abstentions (Cameroon, Eritrea, Hungary, Iran, Libya, Poland, Syria). By its terms, the Assembly would urge States to uphold the civilian and humanitarian character of refugee camps and settlements. It would also call on those that have not yet contributed to burden- and responsibility-sharing to do so, with a view to broadening the support base.

Several delegates, including from the United Kingdom and Portugal, on behalf of a group of countries, expressed regret over the call for a vote on a purely humanitarian text. Norways representative, presenting the text on behalf of the Nordic countries, said it represents a technical rollover of the one approved in 2019. Due to COVID19, and following the Third Committee bureaus guidance, no substantial negotiations were held.

Syrias delegate, however, called for a vote, explaining that his delegation would abstain, as amendments to the drafts substance submitted by Syria and Iran were never entertained. Syria had suggested negotiating in New York on several occasions in hopes of reaching a balanced text. There was no response to our calls, he stressed.

More broadly, the Committee approved several drafts without a vote, among them a draft on literacy, by which the Assembly would urge Governments to cooperate in ensuring that sufficient funds are channelled through existing international financing mechanisms for education including during the COVID19 pandemic and that they also explicitly target and benefit youth and adult literacy.

Among other drafts approved by consensus was one on human rights and extreme poverty, by which the Assembly would call on Member States to design COVID19 recovery strategies and implement gender-responsive social protection and fiscal policies that promote gender equality.

Also approved today were draft resolutions on: trafficking in women and girls; child, early and forced marriage; the human rights treaty body system; the world drug problem; obstetric fistula; female genital mutilation; and protecting children from bullying.

The Committee will reconvene at 10 a.m. on Tuesday, 17 November, to continue its work.

Action

Launching the day, the Committee took up the draft resolution titled Trafficking in women and girls (document A/C.3/75/L.14).

The representative of the Philippines, presenting the draft resolution, said human trafficking robs women and girls of their dignity in the most heinous way, which is why the Philippines applies the full force of law against human traffickers. Her country added a new paragraph on the impact of COVID19 on human trafficking. Online sexual exploitation has significantly increased as a result of lockdowns and restrictions imposed by authorities. However, considering the many challenges of the online platform of the meetings, the Philippines decided to introduce only technical and minor updates to the resolution. She expressed regret over the amendment to operative paragraph 31, which reflects agreed and delicately crafted language. References to sexual and reproductive healthcare services do not necessarily include abortion, she stressed, calling for a victim-centred approach.

The representative of the United States presented amendment L.68, which would delete the words including sexual and reproductive healthcare services from operative paragraph 31.

The representative of Germany, speaking on behalf of the European Union, objected to the amendment, stressing that the reference to sexual and reproductive healthcare services is based on long-agreed language and that trafficking of women and girls has increased during the COVID19 pandemic. The European Union will vote against this amendment, he said, urging all States to do the same.

The representative of Argentina, on behalf of a cross-regional group of countries, expressed surprise over the proposed amendments, as they seek to modify agreed language that stems from the 1994 International Conference on Population and Development. She called for universal access to healthcare services, expressing regret that delegations are forced to vote on this issue and urging Member States to vote against the amendment.

The Committee then rejected draft amendment L.68, by a recorded vote of 120 against to 9 in favour (Libya, Nauru, Palau, Qatar, Russian Federation, Sudan, Syria, Tonga, United States), with 28 abstentions.

The representative of Hungary, stressing the importance of protecting victims and prosecuting perpetrators, disassociated from preambular paragraph 10, underscoring that the causes of migration should be addressed nationally.

The representative of the United States called for an effective implementation of the Protocol to Prevent, Suppress and Punish Trafficking in Persons, Especially Women and Children, supplementing the United Nations Convention against Transnational Organized Crime. Traffickers have exploited COVID19 restrictions for profit, he said, highlighting the vulnerability of women and girls during the pandemic. He disassociated from operative paragraph 31 of the draft resolution as the United States cannot accept references to sexual and reproduction health and healthcare services or any similar language that would promote abortion or recognize the right to abortion. We do not recognize abortion as a method of family planning, he said, noting that there is no international right to abortion. Regarding references to the 2030 Agenda for Sustainable Development and the International Criminal Court, he referred to the United States statement delivered on 13 November, stressing that the United States disassociates from preambular paragraph 10 and does not accept the Global Compact for Safe, Orderly and Regular Migration and objects to such references in the draft. He also opposed the term child prostitution and called for its substitution with the term child trafficking.

The Committee approved the draft resolution on Trafficking in women and girls. By its terms, the Assembly would urge States that have not yet done so to consider ratifying or acceding to the United Nations Convention against Transnational Organized Crime and the Protocol to Prevent, Suppress and Punish Trafficking in Persons, Especially Women and Children.

Among other terms, the Assembly would call on Governments to intensify their efforts to prevent and address, with a view to eliminating, the demand that fosters the trafficking of women and girls, and to put in place or to enhance preventive measures including legislative and punitive measures to deter exploiters of trafficked persons, as well as to ensure their accountability.

The representative of the Russian Federation said she was not convinced that the International Criminal Court represents the appropriate instrument for exercising justice, even if the crimes stipulated in the draft resolution could hypothetically fall under its jurisdiction. The Court must restore its own authority and refrain from a policy of double standards and politicized investigations, he stressed, rejecting the wording in preambular paragraph 16 about the Rome Statute and disassociating from consensus on this paragraph.

The representative of Qatar said her country views operative paragraph 31 from the perspective of national laws and in accordance with its traditions.

The representative of Iraq disassociated from preambular paragraph 16.

The Committee then took up the draft resolution titled Child, early and forced marriage (document A/C.3/75/L.18/Rev.1), which contained no programme budget implications.

The representative of Zambia, introducing the draft, said child, early and forced marriage constituted a grave abuse of human rights. Unfortunately, COVID19 has impeded progress towards eliminating this problem, he said, citing an extremely concerning finding in a report by the United Nations Population Fund (UNFPA), suggesting that the socioeconomic impact of the pandemic would likely generate 13 million additional cases of forced marriage by 2030. We cant afford to see hard-won progress set back, he said. The draft proposed by Zambia and Canada has the support of a cross-regional group of countries, and is a strong, balanced text reached through extensive, transparent negotiations. It contains language concerning the impact of the pandemic on efforts to end harmful practices affecting children, particularly girls, as well as proposals to eliminate such behaviour. Negotiations took place in a collegial manner. Therefore, we are disappointed that some delegations decided to table amendments, which compromises the integrity of principles underlying negotiations, he said, urging that the draft be approved by consensus.

The representative of the Russian Federation, introducing amendments L.77 through L.83, said she is disappointed by the reluctance of those who drafted the text to consider her delegations numerous concerns, thereby forcing her to submit several amendments.

On amendment L.77, she said it proposes changes related to the COVID19 pandemic in preambular paragraph 26.

On amendment L.78, she said it replaces the words humanitarian situations with the words humanitarian emergencies in preambular paragraph 27 and removes the non-factual list of risks faced by girls because of the pandemic, including female genital mutilation and obstetric fistula.

On amendment L.79, she said it proposes changes to operative paragraph 22, aligning new unagreed passages with consensus language from the 2030 Agenda.

On amendment L.80, she said it proposes changes to operative paragraph 23, on measures to be taken against the pandemic, which aim to replace terminology in it with terms mentioned in previous agreements.

Turning to amendment L.81, she said it aims to clarify clear inconsistences in references to children and adolescents in operative paragraph 23(a), by deleting the words and adolescents. Adolescents are also children, she stressed.

Meanwhile, amendment L.82 seeks to delete a reference to marginalized people from operative paragraph 23(c), she said.

On amendment L.83, she said it aims to change vague references to humanitarian settings to humanitarian emergencies in operative paragraphs 21, 23(f) and 26.

These are far from the full list of amendments we would like to be made to the draft, she said. But due to the circumstances, we chose to focus on the most problematic passages in the new paragraphs introduced in the text.

The representative of the United States, introducing amendment L.84, said it proposes alternate language preferred by his country on sexual and reproductive health, contained in many parts of the text, including in operative paragraphs 18 and 23(a). The United States views on this are well known, he stressed.

The representative of Canada said he was confident in the quality of the negotiation process, since 114 co-sponsors had chosen to support it. He expressed deep regret over the many amendments proposed on language that has long enjoyed consensus. Through multiple bilateral consultations, Canada and Zambia made considerable efforts to accommodate other delegations concerns and made an extensive range of deletions to the text. Most proposed changes did not enjoy wide support, he said, adding that it is unfortunate that this same unfair pattern of negotiation by amendment has been witnessed in other drafts. It suggests that it is not the text under consideration that is the problem, he said. The changes proposed by the United States would be irresponsible to make, given that negative outcomes related to provisioning of reproductive and sexual healthcare services are the leading cause of death of girls aged between 15 and 19 worldwide. Therefore, Canada is voting against all proposed amendments, and calls on other States to do so.

The representative of Germany, speaking on behalf of the European Union, welcomed the fair, inclusive consultations by facilitators in which all delegations, including the United States and the Russian Federation, had participated. While no delegation is pleased with the outcome, pushing for changes is not fair to others who accepted compromises, and it undermines the principles of diplomacy, she said. She expressed concern over the numerous attempts made to weaken human rights language in the text, as well as its scope. In particular, she took issue with the proposed change to operative paragraph 23, which would replace the word victim with the word people, which would send a negative signal to all girls, who are subjected to harmful practices, she said, adding that she would oppose all amendments.

The representative of Costa Rica, speaking on behalf of a large crossregional group of countries, expressed regret about the approach of proposing multiple amendments, which goes against the Committees working methods as well as the principles of multilateralism. Language in the text pertaining to health-care services is long agreed upon and must be recognized as striking a balance to accommodate different views on the scope of healthcare needs. Moreover, terms such as sexual and reproductive healthcare services have been used since the 1990s and encompass a wide range of positions. Such attempts to undermine the normative framework underpinning the Committees work is deeply unfortunate. Costa Rica will vote against the amendments and she urged all delegates to vote against them as well.

The representative of the United Kingdom welcomed the new parts of the text, which outline the devastating impact of the pandemic, and said he supported national and international efforts to create inclusive societies for everyone, regardless of their marital status. He expressed deep disappointment with the Russian Federations proposed changes, which are highly disruptive and undermine work done to achieve consensus. He also expressed regret over the amendment proposed by the United States, which touches on consensus language used by the Committee and other United Nations bodies for many years. Any attempt to reduce access to healthcare services to girls, including family planning services, would be detrimental to their health, educational access and life choices, he said.

The representative of Argentina, aligning with the statement made by Costa Rica, said the draft provides alarming figures for child, early and forced marriage, which could have been avoided by 2030. She expressed regret about the last-minute amendments aimed at weakening consensus that was built years ago and are unjust to those who participated in negotiations in good faith. It also sets a bad precedent, she said, adding that she will vote against the amendments and encourages other States to do so. We cannot accept language that restricts the rights of women and girls, she stressed.

The Committee then took up the draft amendment L.77, which it proceeded to reject by a recorded vote of 109 against to 20 in favour, with 31 abstentions.

The Committee then turned to the draft amendment L.78, which proposed changes to preambular paragraph 27, rejecting it by a recorded vote of 111 against to 21 in favour, with 29 abstentions.

The Committee then took up draft amendment L.79, which proposed changes to operative paragraph 22, rejecting it by a recorded vote of 105 against to 26 in favour, with 30 abstentions.

The Committee then took up draft amendment L.80, which proposed to amend operative paragraph 23. It rejected the draft amendment by a recorded vote of 101 against to 29 in favour, with 34 abstentions.

The Committee then turned to draft amendment L.81, which it rejected by a recorded vote of 110 against to 19 in favour, with 31 abstentions.

The Committee then rejected draft amendment L.82, which proposed changes to operative paragraph 23(c), by a recorded vote of 108 against to 23 in favour, with 31 abstentions.

The Committee then rejected draft amendment L.83, which proposed changes to operative paragraphs 21, 23(f), and 26, by a recorded vote of 103 against to 24 in favour, with 37 abstentions.

The Committee then rejected draft amendment L.84, which proposed changes to preambular paragraph 23 and operative paragraphs 14, 17, 18, and 23(f), by a recorded vote of 121 against to 11 in favour, with 32 abstentions.

The Committee then approved draft resolution L.18/Rev.1, on Child, early and forced marriage, without a vote.

By its terms, the Assembly would urge Governments to respect the right to enjoy the highest attainable standard of physical and mental health, through the development and enforcement of policies and legal frameworks and the strengthening of health systems, including health information systems, that make universally accessible and available quality, gender-responsive, adolescent-friendly health services, and sexual and reproductive healthcare services.

By other terms, it would note with concern that child, early and forced marriage disproportionally affects girls who have received little or no formal education, and is itself a significant obstacle to educational opportunities and the development of employable skills for girls and young women in particular, girls who are forced to drop out of school owing to pregnancy, marriage, childbirth and/or childcare responsibilities.

The representative of Germany, speaking on behalf of the European Union in explanation of vote, said girls, especially those who are marginalized, are disproportionately affected by the secondary impact of the pandemic. Their exposure to harmful practices is of serious concern. In the context of the pandemic, girls face a double jeopardy, which sets back hard-won progress in achieving gender equality. She welcomed the action-oriented sections of the text, and its strong human rights focus, as well as its inclusion of proposed additions, which pertain to menstrual hygiene and domestic violence.

The representative of the Russian Federation said her country did not break consensus and is committed to its obligations to eliminate child marriage. However, this important subject is getting contentious due to a group of countries that stuff it with their politicized approaches, she stressed, adding that her main concerns were ignored by the authors of the draft. She expressed regret that mutually respectful dialogue was not possible, adding that she is therefore forced to disassociate from preambular paragraphs 26 and 27, as well as operative paragraphs 21, 22, 26, and 23, including sections (a) to (g). The Russian Federation is not bound by the provisions it disassociates from and does not see them as agreed-upon language in future negotiations.

The representative of the United States said he disassociates from preambular paragraph 23, as well as operative paragraphs 14, 17, 18, and 23(f), because of its concerns about phrasing related to reproductive healthcare services. The United States fully supports voluntary choice but does not recognize abortion as a method of family planning, he said.

The representative of Guatemala said child marriage is a harmful violation of human rights, and noted that her country has reproductive policies, but does not guarantee reproductive rights, nor the right to abortion, which contravenes the legislation of Guatemala.

The representative of Qatar, likewise, said any mention of sexual and reproductive healthcare services in the text must be understood to adhere to the countrys tradition and values.

Meanwhile, the representative of Egypt said she wished to co-sponsor the draft resolution, but that any mention of sexual and reproductive healthcare services must be understood to adhere to the countrys traditions and values.

The representative of Iraq joined consensus on the draft, in compliance with its national laws and resolutions.

An observer for the Holy See expressed disappointment about the inordinate focus on issues that polarize debate and stated his reservation with two concepts used in the draft: References to sexual and reproductive healthcare services must not be understood to include access to abortion, and references to gender must be understood to apply to biological difference.

The Committee then took up the draft resolution titled Human rights treaty body system (A/C.3/75/L.39), which was introduced by the representative of Iceland, on behalf of Belgium and Slovenia. The text is similar to that adopted two years ago as Assembly resolution 73/162 and contains three notable changes.

The Committee then approved draft resolution L.39 without a vote.

By its terms, the Assembly would recognize the valuable role of each of the human rights treaty bodies in the promotion and protection of human rights and fundamental freedoms. It would reaffirm the paramount importance of the equality of the six official languages of the United Nations for the effective functioning of the human rights treaty bodies. The Assembly would reiterate its request that the SecretaryGeneral submit to the General Assembly at its seventy-seventh session a report on the status of the human rights treaty body system.

The representative of Japan said his country attaches great importance to strengthening the human rights treaty system while avoiding unnecessary duplication. It is important to optimize existing resources, which should be provided to the treaty bodies according to resolution 668/268, he said, calling on Member States to actively strengthen the treaty body system.

The Committee then turned to the draft resolution International cooperation to address and counter the world drug problem (document A/C.3/75/L.10/Rev.1).

The representative of Mexico, introducing the omnibus draft, said the issues addressed by the text affect all countries, and that the current version presents technical updates reflecting developments within the Commission on Narcotic Drugs. Mexico would like to strengthen links between specialized bodies in Vienna and discussion within United Nations Headquarters. The pandemic can generate new trends and dynamics in the global drug problem, he warned the Committee, adding that the draft calls for all States to promote a substantive exchange of information related to best practices to counter the global drug problem.

The Committee then adopted L.10/Rev.1 without a vote.

By its terms, the Assembly would reiterate its call on Member States to attain the goals and targets set out in the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem, adopted at its sixty-fourth session. Further, it would call on Member States to engage in cooperation aimed at countering the world drug problem on the principle of common and shared responsibility, urging them to ensure non-discriminatory access to health care and social services in prevention, primary care and treatment programmes.

The representative of the United States, delivering an explanation of vote, disassociated from operative paragraph 81, stressing that Washington, D.C., submitted a notice of withdrawal from the World Health Organization (WHO). He further disassociated from operative paragraph 109 because the text ignores consensus in Vienna and undermines the treaty-mandated obligations of the Commission on Narcotic Drugs.

The Committee then took up the draft resolution titled Literacy for life: shaping future agendas (document A/C.3/75/L.12/Rev.1), which contained no programme budget implications.

The representative of Mongolia, introducing the draft resolution, described literacy as a building block for achieving human rights. It is crucial to promote literacy as an integral part of the right to education, she said, noting that new elements of the draft reflect the progress made in literacy. However, the outbreak of COVID19 has forced schools to close in more than 190 countries, affecting 90 per cent of the worlds students. Many non-literate people have been the hardest hit by the economic, social and educational impact of the pandemic, she added.

The Committee then approved draft resolution L.12/Rev.1 without a vote.

By its terms, the Assembly would urge international development partners and Governments to cooperate in ensuring that sufficient and sustainable funds are mobilized by and channelled through existing international financing mechanisms for education including during the COVID19 pandemic and that they also explicitly target and benefit youth and adult literacy. It also would call on States to implement the 2030 Agenda, including all literacy-related Sustainable Development Goals and targets.

The representative of the United States underscored that the 2030 Agenda is non-binding and does not create rights or obligations under international law, nor does it create any new financial commitments. The United States recognizes the 2030 Agenda as a global framework for sustainable development that can help countries to work towards global peace and prosperity. He welcomed the call for shared responsibility, including national responsibility in the 2030 Agenda, emphasizing that all countries have a role to play in achieving its vision.

Next, the Committee took up the draft Intensification of efforts to end obstetric fistula (document A/C.3/75/L.17).

The representative of Senegal, speaking on behalf of the African Group, introduced the draft noting that SecretaryGenerals reports on the rights of women are a clear representation of the urgent need for action. Citing the health consequences of obstetric fistula, he said the condition mainly affects women in underdeveloped communities. He underscored that the draft has always been adopted by consensus and noted that the current version presents technical updates. As such, he regretted the late submission of amendments and called on Member States to vote against the proposed changes.

The representative of the United States introduced amendments L.73 and L.86, stating that they would replace language on sexual and reproductive health and remove references to UNFPA and WHO. He said the amendments were tabled within the deadline, and the claim that they were last-minute submissions was inaccurate.

The representative of Denmark, speaking on behalf of a group of countries, voiced regret that the amendments would modify agreed-upon language on the scope of womens health needs. Acknowledging that sexual and reproductive health could be controversial issues, she noted that through the 2030 Agenda, States committed themselves to advancing reproductive health rights.

The representative of Germany, speaking on behalf of the European Union, said it goes against the practice of the Committee to present an amendment to a rollover draft. She called for a redoubling of efforts to enhance sexual and reproductive rights, especially as resources for such initiatives have been diverted to address the COVID19 pandemic.

The representative of Senegal said the African Group decided to submit a technical update on the draft that was duly communicated to Member States. He expressed regret that one delegation presented multiple amendments and that those proposed changes had not been presented earlier in the process.

The Committee then decided by a recorded vote of 141 against to 6 in favour (Belarus, Nauru, Qatar, Russian Federation, Tonga, United States), with 18 abstentions, to reject amendment L.73.

By a recorded vote of 153 against to 1 in favour (United States), with 11 abstentions, the Committee also rejected amendment L.86.

The Committee then approved draft resolution L.17 as a whole without a vote. Through its terms, the Assembly would stress the need to address as causes of obstetric fistula the links between poverty, lack of or inadequate education, gender inequality, lack of or inadequate access to healthcare services, including sexual and reproductive healthcare services, early childbearing and child, early and forced marriage. The Assembly would also request the Campaign to End Fistula to develop a road map for accelerating action to end obstetric fistula within a decade, towards achieving the 2030 Agenda.

The representative of Guatemala, delivering an explanation of vote after action on L.17, said she joined consensus on the draft because it underscores the link between poverty and inadequate access to health services for women. She expressed reservations related to operative paragraph 3, as issues of reproductive rights could be misinterpreted.

The representative of the United States said untreated fistula can have devastating effects on women and that his country funds related projects that have helped thousands of women. He expressed regret that the two amendments were rejected, and disassociated from preambular paragraph 9 and operative paragraphs 2 and 3. There is no international right to abortion, he said, adding that the draft must not single out specific organizations, and rather, refer to broader relevant partners.

The representative of Sudan said that, despite her delegations sponsorship of the draft, she believes that States have the sovereign right to implement policies consistent with their national legislation.

The Committee then took up the draft resolution titled Human rights and extreme poverty (document A/C.3/75/L.43/Rev.1), which contained no programme budget implications.

The Committee approved draft resolution L.43/Rev.1 without a vote.

By the text, the Assembly would emphasize that extreme poverty is a major issue to be addressed by Governments, the United Nations, international financial institutions, the private sector, civil society and community-based social organizations. It would reaffirm that political commitment is a prerequisite for the eradication of poverty. Further, it would call on Member States to design recovery strategies based on risk-informed, sustainable financing policies, supported by integrated national financing frameworks in accordance with the Addis Ababa Action Agenda of the Third International Conference on Financing for Development. It would also call on States to implement gender-responsive social protection policies, as well as fiscal policies that promote gender equality and the empowerment of all women and girls.

The representative of the United States welcomed references to persons with disabilities, calling for a more inclusive approach to development. This is particularly important as persons with disabilities are more likely to experience adverse socioeconomic outcomes, which impact their access to health care, education and employment. He further welcomed the integration of the United Nations Guiding Principles on Business and Human Rights in preambular paragraph 22 and operative paragraph 4. Opposing the assertion in preambular paragraph 22 that extreme poverty may amount to a threat to the right to life, he cited article 6 of the International Covenant on Civil and Political Rights, which prohibits arbitrary deprivation of life by State actors.

The representative of Somalia raised a point of clarification. Recalling the principles of universality, impartiality, objectivity and non-selectivity, he clarified that Somalia is not a signatory to a statement on the human rights situation in Belarus. In New York and Geneva, and as a Human Rights Council member and country that advances human rights, Somalia disassociates from that statement.

The Committee then took up the draft resolution titled, Intensification of efforts to prevent and eliminate all forms of violence against women and girls (document A/C.3/75/L.19/Rev.1), which the Chair noted had no programme budget implications.

The representative of the Netherlands, presenting the draft, highlighted the dramatic increase in violence against women and girls during the COVID19 pandemic. The draft expresses an unambiguous condemnation of violence, proposing measures to strengthen collective action. It presents a global compromise, based on agreed language, including on the socalled sensitive issues. We all had to compromise, he said, noting that the text represents delicate balance and inviting all Member States to reject the hostile amendments presented.

The representative of the Russian Federation, introducing amendments L.59 through L.65, turned first to L.59, which concerns preambular paragraph 16 and the phrasing including intimate partner violence that was not discussed during negotiations. Amendment L.60 seeks to address inconsistencies in the wording of preambular paragraph 28 related to paid work for girls. Amendment L.61 concerns operative paragraph 6 (b) and proposes that after the word girls, to add the words with appropriate direction and guidance from parents or legal guardians. Amendment L.62 opposes the term femicide which is not widespread. On the basis of previously agreed language, the Russian Federation proposes to replace the words including femicide with the words also known as femicide in certain regions of the world. Amendment L.63 proposes to delete operative paragraph 11. Amendment L.64 opposes the language of operative paragraph 13. The focus of amendment L.65 is on operative paragraph 17, he said, suggesting to replace the words taking into account their diverse situations and conditions with the phrase while respecting their diverse situations and conditions. The amendments balance and improve the document, she said, calling on States to support them.

The representative of the United States presented amendments L.69 through L.71, explaining that L.69 concerns the final preambular paragraph and proposes to replace the words essential health services with the words responsive interventions to meet their health needs. Amendment L.70 proposed to delete operative paragraph 15. Amendment L.71 focuses on operative paragraph 6 (i), proposing to replace the words comprehensive education that is relevant to cultural contexts with the culturally sensitive, healthfocused sex education and after the words reproductive health add in accordance with national legislation and programmes.

The representative of the United Kingdom welcomed the draft resolutions focus on genderbased violence during the pandemic. She expressed deep disappointment to see multiple amendments seeking to weaken language on sexual and reproductive rights. Opposing the efforts to modify previously agreed language, she rejected the amendments and encouraged all other States to do the same.

The representative of South Africa, also speaking for several other countries, said the proposed amendments contradict the principle of multilateralism and longstanding agreed language. Terminology, such as sexual and reproductive health, was agreed upon in the mid1990s. She expressed regret that Member States have been forced to vote and urged delegations to reject the amendments.

The representative of Egypt, commenting on amendment L.59, said the concept of intimate partner violence remains unclear and not internationally agreed upon. Many countries disassociated from this paragraph during the adoption of the resolution during the Assemblys seventyfirst session, she recalled, expressing surprise to see the concept return during the current session. Egypt will vote in favour of the amendment. On amendment L.62, Egypt does not support the change in agreed language, and thus, will vote in favour of the presented amendment. On L.70, she said Egypt has consistently disassociated from operative paragraph 15 and will vote in favour of the amendment.

Follow this link:
Third Committee Approves 11 Drafts, among Them 4 Covering Women's Rights, Omnibus Text on High Commissioner for Refugees Report, as Myriad Amendments...

Activists Fear Abortion at Risk in Hungary from Orban’s Family-First Crusade – Balkan Insight

Out of the blue

Hungarys sponsorship of the Geneva declaration put the country at the helm of a motley coalition of pro-life hardliners that reject any international obligation on the part of states to finance or facilitate abortion, the document reads.

Most of its 30-odd signatories make up the 20 worst countries around the world for women to live in, according to the Women, Peace and Security Index compiled by Georgetown University. Hungary, ranked 49th, is the third worst among all EU countries and ranks even below the likes of Mongolia and Kazakhstan.

None of the people on the list could care less about women, Gillian Kane from Ipas, an international safe access to abortion advocacy group, summed up for The Guardian newspaper.

The declaration is legally void and does not change any laws already in place. But Hungarys stamp on the family-touting document was still a rude awakening to many, even in the face of the governments years-long pursuit of a policy to spur procreation within predominantly middle-class families with the motif of jumpstarting population growth, Reka Safrany, who chairs the Hungarians Womens Lobby, told BIRN.

Though the governments mounting hostility toward reproduction rights was palpable, we didnt see [the Geneva Consensus Declaration] coming, Safrany added.

Since its return to power in 2010, Orbans government has introduced several obstacles to obtaining an abortion. It wasted no time in slotting language about protecting the foetus since its conception in the constitution, a first for Europe at the time.

Though abortion has remained legal, women can only request the procedure within a narrow set of circumstances, as in the case of grave damage to the foetus, when the mothers health is at risk or when the pregnancy is the result of a crime. Pregnancies can also be mandated by the womans precarious socio-economic situation, which provides a walkable trail for abortions within the public health system in spite of the laws limiting scope, Safrany explained.

The message is clear: if you choose abortion, the state wants you to have it the hard way.

Noa Nogradi, womens rights expert and political philosopher

Women are also subject to mandatory waiting periods and two counselling sessions that are deliberately intended to change minds and dissuade them from going ahead with an abortion. Yet according to research by the PATENT association, a reproductive rights watchdog, these counselling sessions only seem to add to the womens mental strain. Of the more than a hundred women we asked, not a single one came away from it dissuaded. But they all felt humiliated, expert Nogradi, who took part in the study, said.

And its getting harder to book an appointment, even though abortions are extremely time sensitive and you simply cant have the procedure without it, Nogradi added.

Permits for medical abortions that rely on pills have been revoked, leaving many women with surgery as their only option other than going abroad. Nogradi thinks this policy is tinged with ideology. The message is clear: if you choose abortion, the state wants you to have it the hard way.

The past two decades has seen a steady decline in the number of abortions carried out in Hungary. Last year, close to 26,000 pregnancies were surgically terminated in the country, half the tally from 15 years ago, according to the Central Statistical Office. Yet the governments anti-abortion tirade continues.

Minister of Human Resources Miklos Kasler famously blamed abortion for Hungarys population decline, brushing off data that showed the countrys death rate twice outstrips the number of abortions.

And Family Minister Novak has spoken out against abortion in an oft-cited interview with the alt-right website Breitbart. She branded the pro-choice movement as pro-killing and applauded Hungarys family-oriented mentality.

A state-sponsored schoolbook published at the outset of the past academic year reportedly contained several anti-abortion references.

This worldview is reflected in the governments family planning program that offers free in vitro fertilisation to couples in a bid to boost fertility rates. But the policy leaves many people behind, activist Safrany suggests, as its focused on middle-class families. Family planning is also about affordable contraception and adequate education. Why dont these programs have the same backing when many women lack the means to afford them?

The governments family-centric orientation is extreme, Judit Zeller from the Hungarian Civil Liberties Union told BIRN, and could lead to completely shutting out non-married couples or singles from fertilisation treatments.

Conscientious objections to abortions from doctors, often incentivised by government funding, are also on the rise. Yet even in the current legal framework, abortion is a right that should be upheld. After all, abortions are part of the specialists job, thats what they learn at university, Safrany said.

Original post:
Activists Fear Abortion at Risk in Hungary from Orban's Family-First Crusade - Balkan Insight

Songs, sounds and the life of birds – Cosmos

Birds affinity for sound has its upsides and downsides, it seems.

On the one hand, scientists have found that zebra finches have a surprisingly good memory for dozens of different bird songs. Birds that live in forests, on the other hand, can be disrupted by human-made sounds as well as light pollution.

In the first study, published in the journal Science Advances, researchers investigated how many individual bird calls zebra finches could learn to distinguish.

Songbird vocalisations convey different messages sounding an alarm or recognising intruders, for instance as well as unique information about the identity of the vocaliser, like voice recognition in humans.

To make sense of these and identify individuals to form social bonds, its necessary to remember the different sounds. Humans can do that rapidly and retain the auditory memories for long periods of time a process known as fast mapping.

A group from the University of California, US, found that zebra finches can do it as well.

Previously they showed that every call type in the songbirds repertoire is distinctly unique, and that other finches can recognise different individuals. Because the birds are highly social, the team was curious to know how many vocalisers they could tell apart.

We believe that this is an important question because it requires auditory memories for not just particular sounds but for features of sounds that carry information, says senior author Frederic Theunissen, from the University of California.

This is the type of memory that animals and humans need to make for voice recognition and in humans to map sounds to word meanings.

Because they couldnt just ask the birds to identify callers, the team set up an experiment.

They trained 19 adult zebra finches to differentiate calls from unfamiliar vocalisers that were rewarded with food from calls from unrewarded vocalisers. In each trial a different call rendition from each vocaliser was used to make sure the birds could really discriminate between individuals rather than just the different sounds.

Starting with one vocaliser versus another, the team tested them until they used their entire repertoire of 56 vocalisers, finding that the birds could still tell individuals apart 42 on average. The finches were able to make the representations very quickly, after hearing less than 10 call renditions from a new individual, and retain the memories for up to a month.

We found that the memory capacity for vocaliser identity is very high we did not expect this result, says Theunissen. In retrospect, it makes ecological sense because the zebra finch is a gregarious species with strong social bonds with partners and other birds in their group.

Birds are really phenomenal in terms of their skills for vocal communication this study is just one from a long list of studies that have shown these skills.

There is a downside to birds reliance on sounds, though.

Thanks to citizen scientists and the NestWatch program, another team collated a massive amount of data covering 142 bird species from nearly 60,000 nests across North America to clarify how the worlds accelerating noise and light pollution affects them.

After controlling for the impact of other human activities and natural environmental variation, they found that noise and light can profoundly alter reproduction of birds, according to senior author Clinton Francis from California Polytechnic State University.

Anthropogenic noise impairs the perception of auditory signals, altering communication, orientation, foraging and vigilance behaviours, the team writes in the journal Nature.

Similarly, they say, night lighting changes bird activities, circadian rhythms and interactions that rely on vision.

The study showed complex effects depending on where the birds live and how they interact with the environment.

Forest-dwelling birds were most responsive to both stimuli. Noise exposure was associated with fewer eggs and declining nest success and light exposure with earlier nesting and tendency to lay more eggs.

Nesting delays due to noise were strongest in birds with low frequency vocalisations, such as the white-breasted nuthatch songbird, which had lower reproductive success. Human noise has a similar frequency, likely making it harder for them to hear each others breeding cues.

Birds that responded most strongly to light pollution were those that can see well in dim light. They showed advanced breeding with light exposure, and, unexpectedly says Francis says, had greater nest success. The light might have helped them align with plants and insects that emerge earlier as a result of warming temperatures.

The study adds an important perspective to current understanding of climate change impacts on birds, Francis says, which hasnt factored in noise and light pollution and may therefore be inaccurate.

It has strong implications for proposed developments and conservation efforts, he adds.

We should do as much as we can to restore natural sound levels and lighting at night. Unnecessary noise and light should be eliminated or minimised.

Initiatives could include smarter lighting technologies, for instance, to turn lights on only when theyre needed. Noise pollution could be drastically lowered with quiet road surfaces, electric vehicles and increased vegetation near roads.

View original post here:
Songs, sounds and the life of birds - Cosmos